Our findings are consistent with the observations of other authors who have demonstrated elevated serum or plasma levels of MMP-9 in patients with CRC, and decreased plasma MMP-2 levels in CRC patients with metastatic liver disease in comparison to healthy controls [88,89]. This evidence concerns the gene MMP9 and colorectal carcinoma.